Evidence map›Paper›PMID 30324301›Full record

ArticleEuropean journal of clinical pharmacology2019

Trends in concomitant clopidogrel and proton pump inhibitor treatment among ACS inpatients, 2000-2016.

Nawal Farhat, Nisrine Haddad, James Crispo, Nicholas Birkett, Doug McNair, Franco Momoli, Shi-Wu Wen, Donald R Mattison, Daniel Krewski

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of clinical pharmacology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.9field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 26 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Observational
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Nawal FarhatSchool of Epidemiology and Public Health, University of Ottawa, Ottawa, ON, Canada. nfarhat@uottawa.ca.ORCID http://orcid.org/0000-0003-0291-0270
Nisrine HaddadSchool of Epidemiology and Public Health, University of Ottawa, Ottawa, ON, Canada.
James CrispoPerelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Nicholas BirkettSchool of Epidemiology and Public Health, University of Ottawa, Ottawa, ON, Canada.
Doug McNairCerner Corporation, Kansas City, MO, USA.
Franco MomoliSchool of Epidemiology and Public Health, University of Ottawa, Ottawa, ON, Canada.
Shi-Wu WenSchool of Epidemiology and Public Health, University of Ottawa, Ottawa, ON, Canada.
Donald R MattisonSchool of Epidemiology and Public Health, University of Ottawa, Ottawa, ON, Canada.
Daniel KrewskiSchool of Epidemiology and Public Health, University of Ottawa, Ottawa, ON, Canada.
University of Ottawa · CACerner (United States) · USUniversity of Pennsylvania · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe US Food and Drug Administration (FDA) issued three safety announcements between January 2009 and October 2010 warning against concomitant use of clopidogrel and proton pump inhibitors (PPIs) due to a potential drug-drug interaction that may attenuate clopidogrel's antiplatelet activity. This primary objective of this study was to examine trends in concomitant clopidogrel/PPI use among acute coronary syndrome (ACS) inpatients in the US between 2000 and 2016, in relation to the FDA safety communications.

methodsAdult inpatients with a primary diagnosis of ACS were identified from the Cerner Health Facts® database. The standardized (age, sex, race, and census region) prevalence of clopidogrel use with PPIs was calculated yearly and quarterly. Findings were stratified by PPIs' potential to inhibit clopidogrel's activity and by age.

resultsA total of 204,533 inpatients were identified. In 2008, the prevalence of concomitant clopidogrel and PPI treatment was 34.9%, decreasing to 24.4 and 16.4% in 2009 and 2010, respectively, with the decline being similar across age groups. Treatment with inhibiting PPIs (omeprazole and esomeprazole) and clopidogrel has continued to decrease since 2010, with a prevalence of 0.8% in 2016. A similar reduction was not observed with clopidogrel and non-inhibiting PPIs (pantoprazole, lansoprazole, rabeprazole, and dexlansoprazole). During the FDA warning period, the combined treatment with clopidogrel and H

conclusionsFindings suggest that clinical practice recommendations made by the FDA were followed. Further research is needed to determine how changes in drug labels and the availability of new drugs may have influenced the observed trends.

Indexed as

Acute Coronary SyndromeAdolescentAdultAgedAged, 80 and overClopidogrelCross-Sectional StudiesDrug InteractionsDrug Therapy, CombinationFemaleHumansInpatientsMaleMiddle AgedPlatelet Aggregation InhibitorsProton Pump InhibitorsClopidogrelPlatelet Aggregation InhibitorsProton Pump InhibitorsAcute coronary syndromeClopidogrelDrug utilizationMedical recordsProton pump inhibitors

Identifiers

PMID30324301
OpenAlexW2896414613

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.